TriangleCadonilimab (NCT07631000)
Cadonilimab trial for Gastric Cancer (NCT07631000). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, removable HER2-negative gastric or gastroesophageal-junction adenocarcinoma without distant spread. Entry depends on tumor and lymph-node stage. Previous PD-1 or CTLA-4 antibody treatment excludes participation.
The idea: add cadonilimab around surgery to FLOT chemotherapy. Cadonilimab blocks two immune checkpoints, PD-1 and CTLA-4, to support T-cell attack on cancer. Tumor biopsies before and during treatment are required. Researchers assess safety and event-free survival at eighteen months.
This phase 2 study plans 37 patients. Memorial Sloan Kettering lists seven recruiting US locations, six with limited activities.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.